Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Mesoblast Limited MESO

Healthcare  —  Biotechnology
15.12 (0.36) (2.33%) as of 25 Sep
Market cap
$2.0B
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Mesoblast Limited (MESO) Business Profile

Updated before January 2025

Company Overview

Mesoblast Limited (MESO) is a leading biopharmaceutical company specializing in the development and commercialization of innovative cellular medicines. Founded in 2004 and headquartered in Melbourne, Australia, Mesoblast has established itself as a pioneer in regenerative medicine, leveraging its proprietary mesenchymal lineage cell technology platform. The company is publicly traded on the NASDAQ and Australian Securities Exchange (ASX). Mesoblast’s leadership team is composed of experienced professionals in the biotechnology and pharmaceutical industries, with Dr. Silviu Itescu serving as the Chief Executive Officer and Managing Director. Under his leadership, the company has achieved significant milestones in advancing its pipeline of therapies targeting unmet medical needs.

Core Business Segments

Mesoblast operates across several core business segments, focusing on the development of cellular therapies for a range of diseases and conditions. These segments include:

1. Inflammatory Diseases

Mesoblast’s flagship product in this category is remestemcel-L, a mesenchymal stem cell therapy designed to treat severe inflammatory conditions. The product has shown promise in addressing steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children, a life-threatening complication of bone marrow transplants. Remestemcel-L is also being evaluated for other inflammatory conditions, including acute respiratory distress syndrome (ARDS) associated with COVID-19.

2. Cardiovascular Diseases

The company is developing rexlemestrocel-L, a cell therapy aimed at treating chronic heart failure and advanced chronic heart failure with reduced ejection fraction. This therapy has the potential to address significant unmet needs in the cardiovascular space by improving heart function and reducing hospitalizations.

3. Orthopedic Diseases

Mesoblast is advancing MPC-06-ID, a product candidate for the treatment of chronic low back pain caused by degenerative disc disease. This therapy leverages the company’s proprietary mesenchymal precursor cells (MPCs) to address the underlying causes of pain and inflammation.

4. Immuno-Oncology

Mesoblast is exploring the application of its cell therapy platform in the field of immuno-oncology. The company is investigating the potential of its therapies to enhance immune responses against cancer and improve outcomes for patients undergoing immunotherapy.

Business Model

Mesoblast’s business model is centered on the development, manufacturing, and commercialization of cellular therapies. The company integrates its proprietary technology platform with robust clinical development programs to bring innovative treatments to market. Revenue generation primarily comes from licensing agreements, strategic partnerships, and product sales. Mesoblast collaborates with leading pharmaceutical companies and research institutions to accelerate the development and commercialization of its therapies. Additionally, the company has established a scalable manufacturing infrastructure to ensure the consistent production of high-quality cellular products.

Strategic Direction

Mesoblast is committed to advancing its pipeline of cellular therapies to address significant unmet medical needs. The company’s strategic priorities include:

  • Regulatory Approvals: Securing regulatory approvals for its lead product candidates, including remestemcel-L and rexlemestrocel-L, in key markets such as the United States, Europe, and Asia.
  • Pipeline Expansion: Expanding its pipeline to include new indications and therapeutic areas, leveraging its mesenchymal lineage cell technology platform.
  • Sustainability Goals: Implementing sustainable practices in its operations, including reducing its environmental footprint and promoting ethical sourcing of raw materials.
  • Global Market Penetration: Strengthening its presence in global markets through strategic partnerships and collaborations.

Competitive Landscape

Mesoblast operates in a highly competitive biopharmaceutical industry, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Athersys, Inc.: A biotechnology company focused on regenerative medicine and stem cell therapies.
  • Pluristem Therapeutics: A developer of placenta-based cell therapy products.
  • Bluebird Bio: A gene therapy company targeting severe genetic diseases and cancer.
  • Novartis: A global pharmaceutical leader with a strong presence in cell and gene therapies.

Despite the competitive landscape, Mesoblast differentiates itself through its proprietary technology platform, robust clinical pipeline, and focus on addressing unmet medical needs.

Risk Factors

Mesoblast faces several risks that could impact its business operations and financial performance. Key risk factors include:

  • Regulatory Challenges: Delays or failures in obtaining regulatory approvals for its product candidates could hinder commercialization efforts.
  • Market Dependence: The company’s revenue is heavily dependent on the success of its lead product candidates, which are still in the clinical development stage.
  • Supply Chain Disruptions: Disruptions in the supply chain for raw materials and manufacturing components could impact production timelines.
  • Competition: Intense competition in the biopharmaceutical industry could limit market share and pricing power.
  • Financial Risks: As a development-stage company, Mesoblast relies on external funding to support its operations, making it vulnerable to fluctuations in capital markets.

Recent Developments

Mesoblast has made significant progress in advancing its pipeline and corporate strategy. Recent developments include:

  • Regulatory Submissions: The company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for remestemcel-L in the treatment of SR-aGVHD in children.
  • Clinical Trials: Mesoblast has initiated Phase 3 clinical trials for rexlemestrocel-L in chronic heart failure and MPC-06-ID in chronic low back pain.
  • COVID-19 Research: The company has expanded its research efforts to evaluate the potential of remestemcel-L in treating ARDS associated with COVID-19.
  • Partnerships: Mesoblast has entered into strategic partnerships with leading pharmaceutical companies to accelerate the development and commercialization of its therapies.

Investment Considerations

Investors considering Mesoblast as a potential investment should weigh the following strengths and risks:

Strengths

  • Innovative Technology: Mesoblast’s proprietary mesenchymal lineage cell technology platform provides a competitive edge in the regenerative medicine space.
  • Robust Pipeline: The company’s diverse pipeline of product candidates addresses significant unmet medical needs.
  • Strategic Partnerships: Collaborations with leading pharmaceutical companies enhance the company’s development and commercialization capabilities.

Risks

  • Regulatory Uncertainty: Delays or failures in obtaining regulatory approvals could impact the company’s growth prospects.
  • Financial Dependence: Reliance on external funding exposes the company to financial risks.
  • Market Competition: Intense competition in the biopharmaceutical industry could limit market opportunities.

Conclusion

Mesoblast Limited is a pioneering biopharmaceutical company at the forefront of regenerative medicine. With a robust pipeline of innovative cellular therapies and a commitment to addressing unmet medical needs, the company is well-positioned for future growth. However, investors should carefully consider the regulatory, financial, and competitive risks associated with the biopharmaceutical industry. As Mesoblast continues to advance its pipeline and expand its global presence, it remains a key player in the evolving field of regenerative medicine.